Merck Zostavax Gets Mid-Range Price, Loses Younger Age Group
Executive Summary
Merck's newly approved herpes zoster vaccine Zostavax is priced in the middle of the company's cost-effectiveness estimates
You may also be interested in...
Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track
Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said
Merck Q3: Zostavax Nears Part D Hurdles, Gardasil Sales On Fast Track
Merck will seek to drive continued growth of its shingles vaccine Zostavax through promotional activity and efforts to facilitate reimbursement, the firm said
Merck Gardasil Sales Climb In Third Quarter; HPV Vaccine Generates $70 Mil.
Merck's human papilloma virus vaccine Gardasil generated $70 mil. in sales during its first full quarter on the market, the company reported